Rippl’s Post

I'm not sure if this is what we were waiting for: Per an FDA document, treatment-emergent adverse events (TEAEs) were reported by 89% of donanemab-treated patients. The most common AEs were amyloid-related imaging abnormalities (ARIA)–edema/effusions (ARIA-E; 24%), ARIA-hemorrhage/hemosiderin deposition (ARIA-H; 18%), COVID-19 (14%), fall (13%), and headache (13%). Serious AEs were reported by 17% of donanemab-treated patients. To make it worse, in TRAILBLAZER-ALZ clinical trial, 27.5 % experienced ARIA-E and 30.5% of donanemab patients had ARIA-H. Alzheimer's Association should not wait to recommend interventions. Plenty of nonpharmaceutical interventions have been proven to be significantly more effective than Donanemab in well-designed clinical trials. Some even reversed the cognitive decline.

more expensive snake oil to ruin your family savings.

Using Multicountry Ecological and Observational Studies to Determine Dietary Risk Factors for Alzheimer's Disease William B Grant. J Am Coll Nutr. 2016 Jul. Abstract Rates of Alzheimer's disease (AD) are rising worldwide. The most important risk factors seem to be linked to diet. For example, when Japan made the nutrition transition from the traditional Japanese diet to the Western diet, AD rates rose from 1% in 1985 to 7% in 2008. Foods protective against AD include fruits, vegetables, grains, low-fat dairy products, legumes, and fish, whereas risk factors include meat, sweets, and high-fat dairy products. The evidence comes from ecological and observational studies as well as investigations of the mechanisms whereby dietary factors affect risk. The mechanisms linking dietary risk factors to AD are fairly well known and include increased oxidative stress from metal ions such as copper as well as from advanced glycation end products associated with high-temperature cooking, increased homocysteine concentrations, and cholesterol and its effects on amyloid beta, insulin resistance, and obesity. Lower 25-hydroxyvitamin D concentrations also are associated with increased risk of AD https://pubmed.ncbi.nlm.nih.gov/27454859/

For athletes, who generally maintain better cardiovascular health and higher cognitive reserve through regular physical activity, Kisunla may potentially enhance its therapeutic benefits. The drug’s ability to clear amyloid plaques could further support cognitive function in their inactive lifestyle and potentially poorer cardiovascular health might reduce the drug’s efficacy compared to athletes. However, Kisunla’s targeted mechanism against Alzheimer’s pathology could still offer substantial benefits by reducing amyloid burden and potentially improving cognitive outcomes to a certain extent., potentially slowing down cognitive decline more effectively.

 Where does the argument "changes the underlying course of the disease" come from? Based on existing evidence, this is a PR statement without any evidentiary support. The only source of such a statement could be paid advertisement from the manufacturers.

Every drug has its risk factors. Each case must be evaluated individually under close medical supervision.

With the microhemorrhaging observed in some patients, will donanemab be contraindicated for patients with coronary artery disease or hypertension ( as is Leqembi)?

Let’s focus on the fact that there is continuing research being done and breakthroughs actually happening. It was not too long ago that we had years of a dry spell with nothing new to offer for our loved ones suffering with this disease. Find a resource you believe in and donate to this cause to eliminate Alzheimer’s once and for all.

😂 😂 😂

We need to work hard to spread this kinds efforts.